These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34528398)

  • 1. Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations.
    Lyskjaer I; Davies C; Strobl AC; Hindley J; James S; Lalam RK; Cross W; Hide G; Rankin KS; Jeys L; Tirabosco R; Stevenson J; ; O'Donnell P; Cool P; Flanagan AM
    Mol Oncol; 2021 Dec; 15(12):3679-3690. PubMed ID: 34528398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection.
    Gutteridge A; Rathbone VM; Gibbons R; Bi M; Archard N; Davies KEJ; Brown J; Plagnol V; Pillay N; Amary F; O'Donnell P; Gupta M; Tirabosco R; Flanagan AM; Forshew T
    Cancer Med; 2017 Oct; 6(10):2194-2202. PubMed ID: 28834325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
    Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
    Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Profiling Identifies Association of
    Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
    Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
    Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
    J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
    Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
    Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
    Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
    Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
    Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
    Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
    Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M
    J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
    Amary MF; Ye H; Forbes G; Damato S; Maggiani F; Pollock R; Tirabosco R; Flanagan AM
    Virchows Arch; 2015 Feb; 466(2):217-22. PubMed ID: 25432631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synovial chondrosarcoma: a single-institution experience with molecular investigations and review of the literature.
    Gambarotti M; Pacheco M; Ruengwanichayakun P; Silvino Vega Jiménez B; Benini S; Bianchi G; Sbaraglia M; Vanel D; Carretta E; Bertoni F; Franchi A; Dei Tos AP; Righi A
    Histopathology; 2020 Sep; 77(3):391-401. PubMed ID: 32506447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with
    Molenaar RJ; Coelen RJS; Khurshed M; Roos E; Caan MWA; van Linde ME; Kouwenhoven M; Bramer JAM; Bovée JVMG; Mathôt RA; Klümpen HJ; van Laarhoven HWM; van Noorden CJF; Vandertop WP; Gelderblom H; van Gulik TM; Wilmink JW
    BMJ Open; 2017 Jun; 7(6):e014961. PubMed ID: 28601826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
    Lucas CG; Grenert JP; Horvai A
    Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
    Vuong HG; Ngo TNM; Dunn IF
    Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
    Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
    Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
    Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
    Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct IDH1/2-associated Methylation Profile and Enrichment of
    Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
    Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CORR Insights®: Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
    Ramsey DC
    Clin Orthop Relat Res; 2024 Jun; 482(6):957-959. PubMed ID: 38446419
    [No Abstract]   [Full Text] [Related]  

  • 20. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
    Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
    Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.